Liver cancer remains a daunting global health challenge, ranking as one of the leading causes of cancer mortality worldwide. The predominant type, hepatocellular carcinoma, often emerges in the backdrop of chronic liver inflammation and fibrosis due to viral hepatitis, alcohol abuse, or metabolic syndrome. Fibrosis, characterized by excessive deposition of extracellular matrix components, creates a dense, scar-like microenvironment surrounding cancer cells. Far from merely being structural, this fibrotic milieu actively influences tumor biology by modulating cellular behavior, promoting malignant progression, and conferring treatment resistance.

Despite its clinical importance, the molecular crosstalk linking HCC cells to hepatic stellate cells (HSCs)—the principal fibrogenic cell population in the liver—has remained poorly characterized. Previous attempts to target fibrosis therapeutically have been hampered by limited understanding of the signaling networks sustaining this tumor-supportive niche. Addressing this critical knowledge gap, the research team led by Professor Shinji Tanaka leveraged an integrative experimental approach combining clinical sample analysis, single-cell transcriptomics, in vitro cell co-cultures, and genetically engineered mouse models.

Comprehensive gene expression profiling of 372 HCC patient tissues unveiled a striking overexpression of osteopontin (SPP1) in tumors exhibiting advanced fibrosis. SPP1, a secreted glycoprotein implicated in various inflammatory processes, emerged as a key molecular signature correlating with poor clinical outcomes. Immunohistochemical analyses of 103 clinical specimens further substantiated the localization of heightened SPP1 levels specifically within fibrotic tumor regions, underscoring its pathophysiological relevance.

Functionally, experimental elevation of SPP1 production in liver cancer cells accelerated tumor growth and enhanced fibrotic tissue accumulation in murine xenograft models. These observations suggested that tumor-derived SPP1 actively remodels the microenvironment by recruiting and activating HSCs. Cell co-culture experiments convincingly demonstrated that SPP1 secreted by malignant hepatocytes binds directly to CD44 receptors on HSCs, triggering downstream Hedgehog pathway activation—an evolutionarily conserved signaling cascade integral to development and tissue homeostasis.

Activation of Hedgehog signaling was evidenced by upregulation of GLI1, a transcription factor mediating fibrogenic gene expression programs. Pharmacological inhibition of this pathway using vismodegib, an FDA-approved Hedgehog inhibitor, significantly attenuated HSC activation in vivo, reduced fibrotic matrix deposition, and impeded tumor growth. These preclinical results provide robust proof-of-concept for targeting the SPP1–CD44–Hedgehog axis as a viable anti-fibrotic and anti-cancer strategy.

The study’s multidisciplinary methodology enabled an unprecedented high-resolution dissection of tumor-stroma interactions within HCC. Employing single-cell RNA sequencing facilitated the identification of distinct cellular subsets and molecular signatures driving the fibrotic process, while in vitro mechanistic assays unraveled the receptor-ligand interplay fundamental to this axis. Mouse models recapitulated the complex tumor microenvironment, enabling validation of therapeutic interventions in physiologically relevant contexts.

Beyond its mechanistic importance, this research carries profound translational implications. The SPP1–CD44–Hedgehog pathway represents a novel biomarker axis to stratify patients with highly fibrotic HCC, a subgroup traditionally associated with dismal prognosis and limited treatment options. Therapeutic agents targeting components of this signaling cascade could complement existing modalities, potentially overcoming fibrosis-induced drug resistance and improving survival outcomes.

Moreover, this discovery deepens our conceptual understanding of how malignant tumors actively engineer their surrounding stroma to create a supportive niche. Rather than passive bystanders, hepatic stellate cells are co-opted through specific molecular signals to orchestrate fibrosis that fosters tumor expansion and immune evasion. Interrupting this pathological dialogue disrupts the tumor’s ability to exploit the fibrotic microenvironment, offering a novel angle for intervention.

Looking ahead, the research team envisions extending these findings by exploring combinational therapies integrating Hedgehog inhibitors with immune checkpoint blockade or conventional chemotherapeutics. Additionally, elucidating downstream transcriptional targets of GLI1 in HSCs may reveal further actionable nodes within the pro-fibrotic signaling cascade. Expanding clinical trials to evaluate vismodegib or analogous agents specifically in fibrotic HCC patients could rapidly translate these insights into practice.

In summary, the pioneering study conducted by the Institute of Science Tokyo illuminates the critical role of the SPP1–CD44–Hedgehog signaling axis in fostering intratumoral fibrosis and driving hepatocellular carcinoma progression. By unveiling this previously obscure molecular mechanism, the research not only advances fundamental cancer biology but also opens promising therapeutic avenues targeting the tumor microenvironment in liver cancer.

This breakthrough exemplifies the power of integrative experimental frameworks combining molecular biology, genomics, and translational medicine to tackle pressing cancer challenges. As hepatocellular carcinoma incidence continues to rise globally, fueled by emerging epidemics of metabolic liver disease, innovative strategies to mitigate fibrosis and remodel the tumor niche will become indispensable. The newly uncovered signaling axis offers a beacon of hope to patients afflicted with this devastating malignancy.

Institute of Science Tokyo stands at the forefront of such scientific endeavors, committed to advancing knowledge and developing transformative therapies that enhance human health and wellbeing. This landmark publication marks a milestone in the collective effort to decode complex tumor-stroma interactions and heralds a new era of precision oncology for liver cancer.

Subject of Research: Animals
Article Title: Targeting SPP1­CD44­Hedgehog Axis Elicits Therapeutic Effects in Hepatocellular Carcinoma by Suppressing Intratumoral Fibrosis
News Publication Date: 2-Mar-2026
Web References: http://dx.doi.org/10.1111/cas.70296
Image Credits: Institute of Science Tokyo
Keywords: Hepatocellular carcinoma, Liver cancer, Fibrosis, Tumor microenvironment, SPP1, CD44, Hedgehog signaling, GLI1, Hepatic stellate cells, Cancer progression, Experimental study, Therapy

Hepatocellular carcinoma continues to pose a significant clinical challenge worldwide due to its aggressive nature and poor prognosis. While the malignant hepatocytes themselves have been extensively studied, growing evidence implicates the tumor microenvironment (TME) as a vital determinant of cancer evolution and therapeutic resistance. Fibroblasts, being key components of the stromal compartment, contribute not only structurally but also functionally, influencing cancer cell behavior and immune responses. However, the heterogeneity of these fibroblasts within HCC has remained largely unexplored—until now.

Utilizing state-of-the-art single-cell RNA sequencing (scRNA-seq), Jiang and colleagues meticulously profiled fibroblast populations isolated from HCC tumors and adjacent non-tumorous liver tissues. This high-resolution approach allowed the identification of discrete fibroblast subtypes with lineage-specific gene expression signatures, unveiling functional diversity that was previously masked. Their findings underscore that fibroblasts in HCC are not a homogeneous population; instead, lineage-specific subsets distinctively contribute to ECM remodeling and modulate the immune landscape.

The study revealed two major fibroblast stromal subtypes within the HCC TME. The first subtype exhibited a strong profibrotic transcriptional profile characterized by overexpression of collagen and other matrix components, contributing directly to ECM deposition and stiffening of the tumor stroma. This matrix remodeling is pivotal, as a dense, altered ECM not only supports tumor growth and invasiveness but also creates a physical barrier limiting immune cell infiltration and therapeutic drug delivery. Such fibrotic stroma resembles features of liver cirrhosis, emphasizing the harsh microenvironment faced by immune effector cells.

Conversely, the second fibroblast subtype was more immunomodulatory in nature. These cells showed enrichment of chemokines and cytokines implicated in immune cell recruitment and polarization. Intriguingly, this subtype exhibited expression patterns related to immunosuppression, suggesting an active role in establishing an immune-privileged niche that favors tumor immune escape. The dual functionality of these fibroblast subtypes — sculpting ECM architecture while dampening anti-tumor immunity — exemplifies their multifaceted influence on HCC progression.

Dissecting the molecular pathways underpinning these lineage-specific fibroblast functions, the researchers identified key regulatory networks driving stromal cell specialization. Transforming growth factor-beta (TGF-β) signaling emerged as a central axis governing profibrotic fibroblast activation, consistent with its well-documented role in fibrosis and tumorigenesis. Meanwhile, the immunomodulatory fibroblast subtype was associated with heightened NF-κB pathway activity, further linking inflammatory signaling to immune landscape reprogramming.

Beyond mere characterization, the study explored how these fibroblast subsets spatially organize within the tumor milieu using integrative spatial transcriptomics and immunohistochemistry. The profibrotic fibroblasts preferentially localized at invasive tumor fronts, reinforcing their role in ECM remodeling to facilitate metastatic spread. In contrast, immunomodulatory fibroblasts were enriched in perivascular regions, potentially affecting immune cell trafficking and function. This spatial heterogeneity underscores the complexity of stromal-tumor-immune crosstalk in HCC’s ecosystem.

Importantly, the authors demonstrated that the abundance and activation states of these fibroblast subtypes correlated with clinical parameters such as tumor grade and patient survival. Higher expression of fibrotic markers aligned with advanced disease and poorer outcomes, supporting the clinical relevance of their findings. This correlation hints at the therapeutic potential of targeting fibroblast-mediated pathways to disrupt ECM remodeling and improve immune responsiveness in HCC.

In a striking series of functional assays, Jiang et al. manipulated fibroblast subpopulations in ex vivo co-culture models of HCC, observing pronounced effects on tumor cell proliferation and immune cell cytotoxicity. By dampening profibrotic fibroblast activity, there was a notable reduction in collagen deposition and stiffness, enhancing T-cell infiltration and killing efficiency. Conversely, blockade of fibroblast-derived immunosuppressive cytokines revitalized anti-tumor immunity, showcasing promising avenues to exploit stromal vulnerabilities.

These findings provide compelling evidence that distinct fibroblast lineages serve as master regulators within the HCC microenvironment, coordinating the physical and immunological landscapes that either thwart or facilitate cancer progression. The study’s integrative use of single-cell genomics, spatial biology, and functional validation embodies the cutting-edge approach essential for unraveling the multifactorial nature of tumor ecosystems.

From a translational perspective, the delineation of fibroblast heterogeneity opens doors for innovative therapeutic strategies. Targeting the profibrotic fibroblast subset could attenuate the desmoplastic barrier, rendering tumors more accessible to chemotherapies and immunotherapies. Concurrently, modulating the immunosuppressive fibroblast network might potentiate immune checkpoint blockade efficacy by dismantling stromal-induced immune evasion.

Furthermore, the comprehensive fibroblast lineage atlas generated by this study offers valuable biomarkers for patient stratification and treatment monitoring. Imaging agents or liquid biopsy approaches could be developed to non-invasively assess stromal composition, guiding personalized interventions. Ultimately, such stromal-centric paradigms could synergize with existing oncologic therapies to achieve durable clinical responses in HCC.

The revolutionary insight presented by Jiang et al. exemplifies the transformative impact of single-cell technologies in cancer research. Their work not only advances fundamental understanding of stromal heterogeneity in hepatocellular carcinoma but also charts a promising course for stromal-targeted interventions. As the field moves toward integrated, systems-level cancer therapeutics, dissecting and manipulating the tumor microenvironment remains a cornerstone of next-generation oncology.

This study is a clarion call to researchers and clinicians alike, emphasizing the need to transcend tumor cell-centric views and embrace the intricate cellular ecosystems that govern cancer biology. The elucidation of lineage-specific fibroblast subtypes as pivotal architects of ECM remodeling and immune modulation in HCC lays a robust foundation for future explorations aimed at conquering this formidable malignancy.

With hepatocellular carcinoma representing a global health burden with limited effective treatments, the insights from this research spotlight fibroblasts as critical allies or adversaries in cancer progression. Targeting these stromal drivers holds the promise to reshape therapeutic landscapes and improve patient outcomes, heralding a new era where the microenvironment is as actionable a target as the tumor itself.

In conclusion, the elegant integration of cutting-edge single-cell techniques with functional and spatial analyses in this study unravels the complexity of fibroblast subtypes in HCC. As we deepen our understanding of how these stromal cells modulate ECM architecture and immune landscapes, new windows for precision medicine emerge. Jiang et al. have not only illuminated a vital facet of hepatocellular carcinoma biology but also provided a roadmap for harnessing stromal biology to combat cancer more effectively.

Subject of Research: Hepatocellular carcinoma tumor microenvironment, fibroblast stromal subtypes, extracellular matrix remodeling, immune modulation.

Article Title: Single-cell profiling reveals lineage-specific fibroblast stromal subtypes drive ECM remodeling and immune modulation in the hepatocellular carcinoma tumor microenvironment.

Article References:
Jiang, Z., Wang, H., Li, H. et al. Single-cell profiling reveals lineage-specific fibroblast stromal subtypes drive ECM remodeling and immune modulation in the hepatocellular carcinoma tumor microenvironment. Med Oncol 43, 108 (2026). https://doi.org/10.1007/s12032-025-03220-3

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s12032-025-03220-3

The investigation centered around six key RBPs—ILF3, PTBP1, U2AF2, NCBP2, RPS3, and SSB—identified due to their aberrant expression patterns in HCC specimens. By analyzing tissue samples from 28 patients who suffered recurrences after postoperative adjuvant therapy, researchers embarked on a comprehensive quantification of messenger RNA (mRNA) levels of these RBPs, coupling their findings with data from two extensive public clinical datasets. This dual-pronged approach aimed to pinpoint RBPs with the most significant influence on HCC progression and patient prognosis.

Rigorous statistical methods, including Student’s t-test and logistic regression analyses, facilitated the identification of 42 progression-associated RBPs (HPARBPs), shedding light on a network of core regulatory modules intrinsic to the malignant phenotype. The high-throughput nature of these analyses ensured robust confidence in the data, unmasking subtle but mechanistically vital alterations in RNA regulation within cancer cells.

Central to these findings was the application of enhanced cross-linking immunoprecipitation (eCLIP) technology, deployed in HepG2 cell lines, to map the direct interactions between these RBPs and their downstream RNA targets. eCLIP permitted a fine-resolution glimpse into the binding dynamics, revealing that four core HPARBPs exhibited high-affinity binding to RNA transcripts within the RSPO-LGR4/5-ZNRF3/RNF43 module. This signaling module is integral to the Wnt/β-catenin pathway, a critical driver of cell proliferation, differentiation, and tumorigenesis in various cancers, including HCC.

The RSPO-LGR4/5-ZNRF3/RNF43 axis functions as a complex regulatory switch governing Wnt signaling output. RSPO proteins potentiate Wnt signaling by interacting with LGR4 and LGR5 receptors, which in turn regulate the E3 ubiquitin ligases ZNRF3 and RNF43. These ligases target Wnt receptors for degradation, attenuating the signaling cascade. Aberrant modulation by HPARBPs at the RNA level suggests a novel layer of post-transcriptional control over this pathway, underpinning the malignant progression observed in HCC.

Beyond tumor-intrinsic effects, this study delved into the immune microenvironment—the constellation of immune cells infiltrating the tumor milieu, which critically influences cancer growth and response to therapy. Using the CIBERSORT computational algorithm to deconvolute immune cell populations from transcriptomic data, the researchers identified significant shifts in immune cell infiltration patterns correlated with altered RBP expression. These shifts imply that the dysregulation orchestrated by HPARBPs may foster an immunosuppressive niche, enabling tumor evasion from immune surveillance.

Functionally, the RBP-mediated regulation of the RSPO-LGR4/5-ZNRF3/RNF43 module may have downstream consequences beyond canonical signaling. By influencing the abundance and stability of these transcripts, HPARBPs could modulate not only cancer cell intrinsic pathways but also the secretion of cytokines and chemokines that sculpt immune cell recruitment and activation. Such multifaceted regulatory capacity positions these RBPs as critical nodal points for therapeutic intervention.

Clinical relevance was underscored by correlating RBP expression profiles with patient outcomes. The data hinted that patients exhibiting dysregulated HPARBPs and perturbed RSPO-LGR4/5-ZNRF3/RNF43 expression patterns tended to face poorer prognoses and higher recurrence rates post-treatment. These findings advocate for incorporating RBP signatures into prognostic models, potentially guiding personalized therapeutic strategies and risk stratification.

From a translational perspective, RBPs have emerged as druggable targets due to their central role in post-transcriptional gene regulation. The identification of HPARBPs intimately involved in Wnt pathway modulation and immune microenvironment remodeling heralds new avenues for developing RNA-based therapeutics or small molecules to disrupt pathogenic RBP-RNA interactions. Such approaches could complement existing modalities like immune checkpoint blockade or targeted kinase inhibitors, which have shown limited efficacy in HCC due to immune evasion and signaling redundancy.

Notably, this research also advances the methodological toolkit for cancer biology. The integration of eCLIP data with robust computational analyses and clinical correlations exemplifies a systems-level approach necessary for disentangling the complex crosstalk between genetics, epigenetics, and immunology in cancer. The dataset’s depth enables future investigations to explore combinatorial targeting of RBPs alongside other pathways implicated in HCC.

As hepatocellular carcinoma continues to challenge oncologists worldwide, pioneering studies such as this pave the way for reimagining therapeutic landscapes. By elucidating how HPARBPs govern critical signaling axes and immune contexts, the research propels the field toward innovations that not only target tumor cells but also modulate their intricate interactions with the host immune system.

In conclusion, the intricate interplay of RNA-binding proteins within the RSPO-LGR4/5-ZNRF3/RNF43 module emerges as a linchpin of hepatocellular carcinoma progression and immune remodeling. This multifaceted regulatory network offers promising biomarkers for disease monitoring and novel targets for therapeutic intervention. These insights enrich the molecular lexicon of HCC and underscore the pivotal role of RNA biology in shaping cancer evolution and treatment response.

As the field progresses, further exploration of HPARBPs across diverse patient cohorts and experimental models will be vital to translate these foundational findings into clinical successes. Ultimately, integrating RBP-centric strategies could revolutionize HCC management, offering hope for improved outcomes in this relentless disease.

Subject of Research:
The study investigates the role of hepatocellular carcinoma progression-associated RNA-binding proteins (HPARBPs) and their regulation of the RSPO-LGR4/5-ZNRF3/RNF43 signaling module, as well as their influence on the immune microenvironment in hepatocellular carcinoma.

Article Title:
The impact of an RNA-binding protein group on regulating the RSPO-LGR4/5-ZNRF3/RNF43 module and the immune microenvironment in hepatocellular carcinoma

Article References:
Xie, Z., Dai, Z., Liu, Z. et al. The impact of an RNA-binding protein group on regulating the RSPO-LGR4/5-ZNRF3/RNF43 module and the immune microenvironment in hepatocellular carcinoma. BMC Cancer 25, 751 (2025). https://doi.org/10.1186/s12885-025-13874-x

Image Credits: Scienmag.com

DOI:
https://doi.org/10.1186/s12885-025-13874-x

Keywords:
RNA-binding proteins, hepatocellular carcinoma, RSPO-LGR4/5-ZNRF3/RNF43 module, Wnt signaling pathway, immune microenvironment, post-transcriptional regulation, eCLIP, tumor progression, immunoinfiltration